Loading…
Product type
Bevacizumab biosimilar API is a biotechnology-derived active pharmaceutical ingredient used in the production of biosimilar medications that mimic the effects of the original Bevacizumab. It is produced using living cells through recombinant DNA technology, ensuring a complex structure that closely resembles the reference product. This API is typically utilized in the treatment of various cancers by inhibiting angiogenesis, the process through which tumors develop their own blood supply.
| Form | Lyophilized powder |
| Purity | Typically ≥ 95% |
| Storage conditions | 2°C to 8°C |
| Shelf life | 24 months from the date of manufacture |
| Production method | Recombinant DNA technology |
When selecting a Bevacizumab biosimilar API, buyers should consider the specific grade required for their formulations, as well as any relevant regulatory approvals and certifications. It is important to specify the desired purity levels, storage conditions, and shelf life when requesting a quote. Additionally, buyers should indicate the quantity needed for their production processes to ensure accurate pricing and availability.
Get quotes for Bevacizumab Biosimilar API
Tell us your requirement — quantity, specs and timeline — and our team sources verified manufacturers and brings you the best quote.
A biosimilar API is a biologic medical product highly similar to an already approved reference product.
It is produced using recombinant DNA technology in living cells.
It is primarily used in oncology for cancer treatment.
Typical purity levels are ≥ 95%.
It should be stored at 2°C to 8°C.
The shelf life is generally 24 months from the date of manufacture.